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ABSTRACT
Although antibacterial research has declined in many larger pharmaceutical companies, small
companies have begun to ﬁll in the gap. Antibacterial discovery research is currently being conducted
in at least 35 small companies. One successful approach taken by small pharma has been to continue
clinical programmes that were abandoned by large companies. Issues surrounding these activities, as
well as proposed changes, are outlined.
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THESIS
Due to market pressures, antibacterial drug dis-
covery has declined in many large pharmaceutical
companies (pharma) and is shifting to small
pharma. There are a number of small companies
pursuing antibacterial discovery and development
using a variety of approaches, and they are likely
to be successful in identifying or creating useful
new chemical entities (NCEs) in the next several
years. The most advanced of these are modiﬁca-
tions of existing antibacterial scaffolds addressing
the current resistance problems in Gram-positive
bacteria. Very few companies can afford to pro-
gress their current development programmes and
simultaneously maintain a discovery programme
looking for novel substances active against Gram-
negative bacteria.
This shift from large pharma to small pharma
has occurred because antibacterials in theUSA and
Europe are facing classic market failure. The
plethora of discovery programmes initiated in the
postgenomic period has failed to lead to an easy or
rapid source of new antibacterials. With a few
notable exceptions, antibacterials cannot guarantee
a return on investment consistent with the needs of
today’s large pharma or even investors in small
pharma. Most markets facing this scenario die a
natural death. In this case, the public health
implications and the very long lead-time required
to bring a drug to market should preclude the
abandonment of antibacterial drug discovery.
Scope
We explore some current approaches undertaken
by small pharma, the issues common to this ﬁeld,
the advantages and disadvantages small pharma
have over their large pharma counterparts, and
the factors or changing paradigms that may force
an inﬂection point in the antibacterial market-




Despite the exodus of large pharma from the
antibacterial ﬁeld,many small companies continue
to focus their efforts on antibacterials. The most
visible of these are efforts to continue clinical
programmes abandoned by large pharma; the
model for this is the efforts of Cubist who success-
fully completed a clinical programme and regis-
tration of Lilly’s original discovery, daptomycin,
pioneering a new dosage regimen to control the
toxicity observed by Lilly. Several companies are
attempting to follow in their footsteps, e.g., Oscient
Pharmaceuticals (gemiﬂoxacin), Replidyne
(faropenem), Peninsula (doripenem), Intermune
(oritavancin), and this is further exempliﬁed by
companies developing antifungals, e.g., Vicuron
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Table 1. Antibacterial discovery in small pharma
Company Products, technology, focus Website
ActivBiotics In-licensed rifalazil, novel rifamycins http://www.activbiotics.com
Adaptive Therapeutics Adaptides (small cyclic peptides) http://www.adaptivetherapeutics.com
Afﬁnium Therapeutics ‘Galapagos’, ‘Rockhopper’ programmes http://www.afnm.com
Anacor Novel boron chemistries for antibacterial and
antifungals
http://www.anacor.com
Anadys Pharmaceuticals Ribosome inhibitors, cell wall biosynthesis inhibitors,
Riboproteomics, SBDD*, screening
http://www.ansdyspharma.com
Arpida Ltd In-licensed iclaprim, bacterial genomics, and
screening
http://www.arpida.ch
Arrow Therapeutics Aromatic amino acid pathways http://www.arrowt.co.uk
Basilea In-licensed BAL9141 http://www.basilea.com
Biosynexus Topical antistaphylococcal enzyme lysostaphin http://www.biosynexus.com
Blanca Preclinical carbacephem, BP-102, in-licensed from
Trine Pharmaceuticals
Cetek Corporation Screening of Natural Products using capillary
electrophoresis for antifungals
http://www.cetek.com
Cubist Natural products; in-licensed daptomycin
(CidecinTM)
http://www.cubist.com
Cumbre Rifamycine active in bioﬁlm infections, CBR 1477 http://www.cumbre.net
Cytogenix Triplex forming oligonucleotides to inhibit
expression of bacterial cell division
http://www.cytogenix.com
Enanta Pharmaceuticals Macrolide chemistry, EP013420 http://www.enanta.com
Exponential Biotherapies Bacteriophage http://www.expobio.com
Fasgen Fatty acid biosynthesis, antimycobacterials http://www.fasgen.com
Gangagen Bacteriophage http://www.gangagen.com
Inimex Structure-based drug design http://www.inimexpharma.com
Intermune In-licensed liposomal amphotericin, oritavancin and
immunomodulators
http://www.intermune.com
Ipsat Therapies Bioengineered enzyme to destroy unabsorbed
antibiotic from the GI tract
http://www.ipsat-ther.com
Kosan Biosynthetic polyketides http://www.kosan.com
MethylGene Beta-lactamase inhibitors http://www.methylgene.com
Migenix Cationic peptides, lipopeptides http://www.mbiotech.com
MPEX Pharmaceuticals Efﬂux pump inhibitors for potentiation of antibacterials http://www.mpexbio.com
Mutabilis Anti-virulence http://www.mutabilis.fr





peptide deformylase inhibitors, DNA binder
http://www.oscient.com
Paratek Pharmaceuticals Targeting multiple antibiotic resistance operon and
tetracycline derivatives, PTK0796
http://www.paratekpharm.com
Peninsula Pharmaceuticals A carbapenem (doripenem) and a cephalosporin
(PPI-0903) in-licensed from Shionogi and
Takeda, respectively
http://www.peninsulapharm.com
PhageTech Bacteriophage genomic screening for target
identiﬁcation
http://www.phagetech.com
PharmAthene Dominant negative inhibitors for anthrax http://www.pharmathene.com
Quorex DNA gyrase B inhibitors, structure-based drug design http://www.quorex.com
Rib-X SBDD targeting ribosomes http://www.rib-x.com
SelectX Natural product-like libraries, resistance prediction
technology
http://www.selectxpharm.com
Theravance Multivalent drugs http://www.theravance.com
Sequella Second generation of the anti-TB drug ethambutol http://www.sequella.com
Siga Technologies Anti-virulence, and leads targeting bacterial
sortase, (G+) and bacterial pilus formation (G–)
http://www.siga.com
Strata In-licensed MBI-226 (cationic peptide) from migenix




In-licensed ramoplanin, dalbavancin; peptide
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(anidulafungin) and Diversa (sordarins). Discov-
ery technologies include a return to natural prod-
ucts, genomics-based efforts or activity on leads
derived therefrom, optimisation of synthetic leads,
rational drug design or optimisation, antimicrobial
peptides, phage technologies, and probiotics (see
Table 1). Below we review selected companies
undertaking some of these efforts.
Basilea
Basilea Pharmaceutica (Basel, Switzerland) is the
spinout of Roche’s antibacterial efforts in Europe.
Arriving on the scene with a well-ﬁlled discovery
pipeline, a critical mass of trained personnel, and
equity investment from the parent company, Bas-
ilea quickly found footing in the investment com-
munity. Their lead product, an anti-MRSA
(methicillin-resistant Staphylococcus aureus) cepha-
losporin (BAL5788), has completed Phase II trials
and received fast-track designation from the US
FDA. Their discovery pipeline is populated with
twomore b-lactams, amacrolide targeted for use in
acne, and a programme in leader peptidase inhib-
itors.
Paratek
Paratek Pharmaceuticals (Boston, MA, USA) has
two main approaches in antibacterials. The ﬁrst
programme is focused on the creation of new
tetracycline derivatives with activity against resist-
ant organisms, and the secondprogrammeexploits
their discovery of the Multiple Antibiotic Resist-
ance or mar operon, a novel ‘master switch’ that
controls a large set of genes in a number of
important disease-causing Gram-negative bacteria
(such as Salmonella, Shigella and Escherichia coli).
Paratek recently executed a Collaborative Devel-
opment Agreement with Bayer AG and Bayer
HealthCare Corporation for the development of its
lead tetracycline-derived antibacterial, PTK 0796.
Compounds active against themar locus are inten-
ded for use in combination with existing drugs as
therapeutics or alone as a prophylactic.
Enanta
Enanta Pharmaceuticals (Watertown, MA, USA)
has developed a single step ring contraction of 16-
membered macrolides to 14-membered macro-
lides. There are more than 20 commercially
available 16-membered macrolides for this ring
contraction reaction. These new macrolides have
activity against Streptococcus pneumoniae, S. aure-
us, Streptococcus pyogenes and Haemophilus inﬂuen-
zae, particularly against resistant strains mediated
by efﬂux.
EP-013420, a bridged bicyclic ketolide (BBK) has
broad coverage against respiratory pathogens
including macrolide- and penicillin-resistant
S. pneumoniae (PRSP), S. pyogenes, H. inﬂuenzae
and atypical respiratory pathogens. In addition,
this compound has in vitro activity against many
strains of multidrug-resistant S. pneumoniae, inclu-
ding strains resistant to the traditional macrolides,
penicillins and ﬂuoroquinolones. Enanta initiated
Phase I clinical trials for EP-013420 in August 2004,
prior to initiating studies as a ﬁrst-of-class antibac-
terial, for the treatment of community respiratory
tract infections. In July 2004, Enanta announced
that theyhadout-licensed to Shionogi the exclusive
Asia Territory rights for EP-013420.
Afﬁnium
Afﬁnium Pharmaceuticals (Toronto, Canada) is
a structure-guided drug discovery company
focused on the development and commercialisa-
tion of novel anti-infective medicines and the
inheritor of the well-developed Fab I inhibitor
programme that arose out of SKB’s genomics
efforts.
To date, their Galapagos Programmes claim
intellectual property, high-resolution target struc-
tures, and unique chemistry with activity against
staphylococci. Features of the programme include:
• excellent antibacterial activity (MICs <
0.006 lg ⁄mL) against staphylococci including
CoNS (coagulase negative staphylococci),
MRSA, VISA (vancomycin-intermediate
S. aureus), and VRSA (vancomycin-resistant
S. aureus);
• oral bioavailability; some compounds with
in vivo oral efﬁcacy;
• low frequency of resistance, signiﬁcant post
antibiotic effect, and no antagonism with other
commercially available antibiotics;
• no signiﬁcant toxicity observed.
ISSUES FACED BY THIS FIELD
Most people involved in the ﬁeld of infectious
disease research would agree that a long-term
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solution to theproblemofdrug resistancedemands
novel chemical classes rather than ‘me-too’ drugs.
However, the natural and inevitable evolution of
resistance might be slowed by the availability of
modiﬁcations of existing classes. While current
medical practice makes empirical therapy a
necessity, the availability of narrow-spectrum
agents and their appropriate use may also help
slow the progression of resistance. If new broad-
spectrum antibacterials do become available, their
use will inevitably be restricted; however, this
alone provides a signiﬁcant disincentive to their
discovery. This is particularly true for large
pharma, but also applies to small pharma. Cur-
rently, most small pharma companies rely on
licensing their products to large pharma, but if
projected sales are not large, they will need to
develop their ownmarketing and sales capabilities.
Once again, Cubist has shown the way forward in
this particular model with daptomycin. However,
this process will inevitably reduce resources avail-
able for future discoveries in the short term.
Economic drivers are completely at odds with
medical and social goals in anti-infectives. Infec-
tious diseases are largely acute illnesses, and the
short therapeutic coursesmake it difﬁcult for drugs
to reach blockbuster status. In addition, this is a
maturemarket litteredwith low-price generics. It is
a highly fragmented market for susceptible organ-
isms but with poor coverage of emerging resistant
organisms. Because regulatory agencies grant
approval for the treatment of medical indications
instead of for the coverage of resistant organisms, it
is necessary to develop a newdrug that is all things
to all people – comparable in efﬁcacy with a gold
standard agent on an intent-to-treat analysis of
patients harbouring organisms that are largely
susceptible to the comparator drug, competitive
with on-market agents with respect to dosing
interval, side-effects and price.
Add to this the woes encountered by drug
hunters in all ﬁelds. Patent life is almost identical
to the timeline for bringing a drug from discovery
to market. Recuperation of cost is almost imposs-
ible for a drug that is not able to reap large returns
in the ﬁrst several years on market.
DRIVERS FOR CHANGE
For many years, antibiotic resistance was largely
seen in hospital-acquired infections. Increasingly,
community-acquired infections are showing
resistance (e.g., PRSP, MRSA). This trend is likely
to increase in the USA and Europe, where an
ageing population is becoming more susceptible
to infection. In addition, the USA has documented
an alarming increase in obesity and an increase in
Type II diabetes is also predicted. These patient
populations are more susceptible to infection and
less able to ﬁght infection. Thus, over the long-
term, this market opportunity is likely to continue
to grow.
The inﬂux of biodefence funding may allow the
development of dual use agents (for bioterror and
community ⁄nosocomial infections). This is espe-
cially welcome in that supported programmes are
likely to focus on novel classes for which engin-
eered resistance has not been attempted and for
which natural resistance may not yet have
occurred.
Despite these drivers, radical changes will be
required to revive this market. Some examples
include the following.
Implementation of more rapid diagnostics in clinical
settings. The rapid identiﬁcation of not only the
organism but also its susceptibility would allow
the use of narrow spectrum agents.
Interim public health investment funding for drug
discovery and development. Even a qualitative
market analysis reveals why so many large
pharmaceutical companies have exited the ﬁeld.
If we accept that the commercial market is
elusive at best, and acknowledge the public
health implications and the lead times involved
in creating new drugs, one concludes that this
endeavour must become publicly funded. This
may even require public health contracts to
purchase new antibacterials during a gap if the
market is not resuscitated by changes in such
features as patient populations and pricing.
Re-examination of patent life and scope. Patents and
patent life were surely designed with products
that could more rapidly be reduced to practice
in mind.
Revised regulatory incentives and guidance. The need
for agents that address resistant organisms
must be recognized by the FDA and separated
from the desire to approve only compounds
that can compete in treating an entire clinical
indication.
New pricing structure to reﬂect restricted use. If we
are to use new agents sensibly (an agenda that
can only be effectively implemented with more
rapid diagnostics for resistance), and if we
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wish to revive the commercial markets rather
than publicly fund all antibiotic drug discovery
and development, then we need to provide a
commercial incentive.
SMALL PHARMACEUTICAL
COMPANIES : HOW DO THEY FARE
ON THE ISSUES?
Overall, small pharmaceutical companies remain
passionate about creating new antibacterials to
address drug resistance. They are dedicated to
using their agility and low overhead to allow them
to reap the rewards available from the smaller
markets available to niche antibacterials, and they
dream of hitting a blockbuster drug. While
addressing resistance is high among their goals,
only a few are actually working on new classes of
agents. Fewer still are willing to venture simulta-
neously into the diagnostics arena, which is seen
as a separate business model but one which we
believe is key in moving the ﬁeld forward.
Despite their persistence and passion, small
pharma are poorly equipped to deal with the
remaining issues or to drive change at a high
level. Their response has been to do what is
possible for them (i.e., choose late-stage, low-
risk projects that can be ﬁnanced by their
traditional sources). Unfortunately this usually
means short-term solutions to a long-term prob-
lem. Thus, it would seem that small pharma
will provide some parts of the solution to the
antibacterial discovery dilemma that we are
currently facing but that they will need imag-
inative and innovative help if we are to ﬁnd a
long-term solution.
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